II. Indications
- Onchocerca Volvulus
-
African Trypanosomiasis
- Stage 1 East African Trypansomiasis only in age < 6 years or weight <20 kg
- Fexindazole is preferred as first-line therapy in most other cases of trypanosomiasis
III. Mechanism
- Polysulphonated naphthylurea
-
Antiparasitic activity (primary use)
- Used in limited cases of African Trypanosomiasis
- Possible antineoplastic activity
- Suramin blocks growth factor binding
- Inhibits endothelial cell proliferation and migration
- Insulin-Like Growth Factor I (IGF-I)
- Epidermal growth factor (EGF)
- Platelet-derived growth factor (PDGF)
- Tumor growth factor-beta (TGF-beta)
- Inhibits Angiogenesis
- Inhibits endothelial cell proliferation and migration
- Other Suramin effects
- Inhibits Retroviral reverse transcriptase
- Inhibits topoisomerases
- Inhibits steroidogenesis
- Suramin blocks growth factor binding
IV. Pharmacokinetics
- Does not cross the blood brain barrier (no CNS Infection effects)
V. Dosing
- First Test Dose: 5 mg/kg IV and observe for Hypersensitivity Reaction
- Next: 20 mg/kg (up to 1 g) on days 1, 3, 7, 14 and 21
VI. Adverse Effects
- Serious
- Common
- Fever
- Malaise
- Joint Pain
- Rash
- Headache
- Paresthesias
- Nephrotoxicity
- Hepatotoxicity
VIII. Resources
IX. References
- Gladwin, Trattler and Mahan (2014) Clinical Microbiology, Medmaster, Fl, p. 349
- (2025) Sanford Guide, accessed 7/11/2025 on IOS
- Ortiz-MartÃnez (2023) Curr Trop Med Rep 10(4):222-34 +PMID: 38939748 [PubMed]